MK-677 (Ibutamoren) and Caffeine Interaction: What the Evidence Shows

What Is MK-677 and How Does It Work?

MK-677 is an orally active, non-peptide ghrelin-receptor agonist that stimulates pituitary release of growth hormone (GH) and downstream insulin-like growth factor-1 (IGF-1). It does not suppress the hypothalamic-pituitary axis the way exogenous GH does. A 24-month randomized controlled trial by Murphy et al. (N=65 elderly adults) found that 25 mg daily raised IGF-1 levels by roughly 40% and increased lean body mass without significant change in fat mass over two years 1.

Receptor Target and Selectivity

MK-677 binds the growth hormone secretagogue receptor 1a (GHSR-1a) with high selectivity. GHSR-1a is expressed in the pituitary, hypothalamus, hippocampus, and GI tract 2. Activation mimics endogenous ghrelin but with a longer half-life of roughly 24 hours, enabling once-daily oral dosing.

IGF-1 Dose-Response

Doses studied in published trials range from 10 mg to 50 mg daily. Doses of 25 mg appear to produce near-maximal IGF-1 stimulation in most adult populations. A Phase II crossover study by Chapman et al. (N=32 older adults) reported that 25 mg raised mean 24-hour GH area-under-the-curve (AUC) by approximately 97% compared to placebo 3.

Regulatory Status

The FDA has not approved MK-677 for any therapeutic indication. It has been investigated under Investigational New Drug applications, and the FDA's Drugs@FDA database confirms no approved NDA or ANDA exists for ibutamoren 4.

Caffeine Pharmacology: A Brief Review

Caffeine is a methylxanthine that competitively antagonizes adenosine A1 and A2A receptors. Its average plasma half-life in healthy adults is 3 to 7 hours, though CYP1A2 polymorphisms can extend this to 10 to 12 hours in slow metabolizers 5.

CYP Enzyme Profile

Caffeine is metabolized primarily by CYP1A2 in the liver, producing paraxanthine (84%), theobromine (12%), and theophylline (4%) as primary metabolites 5. MK-677, by contrast, is metabolized primarily through CYP3A4 6. Because these two drugs use different CYP isoforms, competitive metabolic inhibition between them is not expected.

Adenosine and Sleep Architecture

Adenosine accumulates in the brain during wakefulness and promotes sleep pressure. Caffeine blocks this signal. A randomized, double-blind, crossover trial by Drake et al. (N=12, published in the Journal of Clinical Sleep Medicine) found that 400 mg of caffeine taken 6 hours before bedtime reduced total sleep time by 41 minutes compared to placebo, with a measurable suppression of slow-wave (N3) sleep 7.

The Core Interaction: Sleep Architecture and GH Pulsatility

This is where the MK-677 and caffeine interaction becomes clinically meaningful. MK-677 does not produce a flat, sustained GH elevation. It amplifies the pulsatile GH release that naturally occurs during slow-wave sleep.

GH Secretion During N3 Sleep

Roughly 70% of daily GH secretion in healthy adults occurs during the first slow-wave sleep cycle, typically 60 to 90 minutes after sleep onset 8. MK-677 amplifies this pulse. If slow-wave sleep is shortened or delayed by caffeine, the amplitude of that GH pulse shrinks with it.

Caffeine's Documented Effect on Slow-Wave Sleep

The Drake et al. Trial cited above is the most frequently referenced controlled study on this question 7. Caffeine consumed 0, 3, or 6 hours before bed all produced statistically significant reductions in sleep quality. The 6-hour pre-bed dose still reduced total sleep time by a measurable margin, though smaller than the 0-hour or 3-hour conditions.

A separate polysomnography study by Landolt et al. Found that even 200 mg of caffeine in the morning reduced subsequent slow-wave activity (SWA) that night 9. SWA is the EEG marker of deep sleep depth and is directly correlated with GH pulse amplitude.

Practical Implication for MK-677 Users

If MK-677 is taken at night to align with natural GH pulsatility, consuming caffeine in the afternoon or evening may reduce the drug's functional benefit without altering its pharmacokinetics. The drug is still absorbed and still stimulates the pituitary; the downstream GH pulse is simply smaller because the sleep stage that gates it is compromised.

Cortisol Dynamics: A Secondary Overlap

Both caffeine and MK-677 affect the hypothalamic-pituitary-adrenal (HPA) axis. This secondary overlap is underappreciated.

Caffeine and Cortisol

A controlled study by Lovallo et al. (N=48) found that 300 mg of caffeine raised salivary cortisol by approximately 30 to 40% in both rested and sleep-deprived participants 10. The effect was more pronounced in habitual non-coffee-drinkers but remained significant in habitual users.

MK-677 and Cortisol

MK-677 has a mixed cortisol profile. The Murphy et al. 2-year RCT found a small but statistically significant increase in fasting cortisol at 25 mg daily 1. The Endocrine Society's clinical practice guideline on growth hormone deficiency notes that ghrelin-receptor agonists can modestly stimulate ACTH, which secondarily raises cortisol 11.

Combined Effect

Stacking two agents that both raise cortisol, even modestly, may present a concern for users who are also managing stress, sleep deprivation, or metabolic syndrome. Elevated cortisol opposes GH action at the tissue level by increasing IGF-1 binding protein-1 (IGFBP-1) and reducing GH receptor sensitivity. This does not mean the combination is dangerous for otherwise healthy adults, but it does mean that heavy caffeine use may partially offset MK-677's anabolic signaling through an HPA-axis mechanism separate from sleep disruption.

Pharmacokinetic Interaction: Direct Assessment

To be direct: no published pharmacokinetic drug-drug interaction (DDI) study exists specifically for MK-677 and caffeine. The interaction framework below is derived from first principles and published data on each agent individually.

CYP3A4 vs. CYP1A2: No Competitive Inhibition

MK-677 is a CYP3A4 substrate. Caffeine is a CYP1A2 substrate. Neither drug is a clinically meaningful inhibitor or inducer of the other's primary metabolic enzyme at typical doses 65. A systematic review of CYP interactions by Lexicomp and the FDA's drug interaction guidance confirm that CYP1A2 activity does not meaningfully alter CYP3A4 clearance 12.

Protein Binding

MK-677 is approximately 97.5% plasma protein-bound. Caffeine binds modestly to plasma proteins (approximately 35%). At these differing binding affinities and typical therapeutic concentrations, displacement interactions are not expected.

P-glycoprotein (P-gp)

MK-677 is a substrate of P-gp efflux transporters. Caffeine does not meaningfully inhibit P-gp at doses consumed in beverages. No clinically significant alteration of MK-677 bioavailability from caffeine via this pathway is anticipated.

Blood Glucose and Insulin Sensitivity: A Third Overlap

MK-677 is known to increase fasting blood glucose and reduce insulin sensitivity. In the Chapman et al. Phase II study, fasting glucose rose by approximately 0.3 mmol/L (5.4 mg/dL) at 25 mg daily 3. This is a reproducible finding across multiple trials and appears dose-dependent.

Caffeine and Insulin Sensitivity

Acute caffeine ingestion impairs insulin-mediated glucose disposal. A randomized crossover study by Keijzers et al. (N=12 healthy volunteers) found that caffeine infusion equivalent to approximately 5 mg/kg reduced whole-body glucose uptake by 24% during a euglycemic hyperinsulinemic clamp 13. This effect is acute and largely reverses with habitual consumption due to adenosine receptor upregulation.

Combined Glucose Impact

Users with pre-diabetes or impaired fasting glucose should be aware that both agents can independently raise blood glucose. The American Diabetes Association's Standards of Medical Care note that caffeine acutely impairs glycemic control and recommend monitoring in at-risk individuals 14. Adding MK-677 to a high-caffeine pattern may compound this effect, particularly in the first 4 to 8 weeks of MK-677 use before metabolic adaptation occurs.

Blood Pressure and Cardiovascular Considerations

Neither MK-677 nor caffeine is classified as a cardiovascular drug, but both affect hemodynamics.

Caffeine and Blood Pressure

A meta-analysis of 34 randomized trials (N=2,496) published in the Journal of Hypertension found that 200 to 300 mg of caffeine raised systolic BP by 3.5 mmHg and diastolic BP by 2.0 mmHg acutely in non-habitual users 15. Tolerance develops with daily use, largely attenuating this effect.

MK-677 and Blood Pressure

The 2-year Murphy et al. RCT did not report clinically significant changes in systolic or diastolic BP at 25 mg daily 1. GH and IGF-1 elevation can promote sodium retention through renal tubular effects, which may modestly increase intravascular volume.

Combined Hemodynamic Effect

No published trial has studied the combined hemodynamic effect of MK-677 plus caffeine. For users with controlled hypertension, monitoring BP during the first 4 weeks of combination use is a reasonable clinical precaution. The American Heart Association's guidance on dietary stimulants recommends caution with any compound that acutely raises BP in individuals with Stage 1 hypertension (systolic 130 to 139 mmHg) 16.

Anxiety, Cortisol, and GH: The Adrenal Axis Triangle

Anxiety and elevated cortisol are among the most commonly reported subjective side effects on MK-677 forums, and caffeine is a well-established anxiogenic at doses above approximately 400 mg/day 17.

GH and Anxiety

Elevated GH itself may increase arousal in some individuals through IGF-1 effects on limbic circuits. A review of GH deficiency replacement therapy published in the Journal of Clinical Endocrinology and Metabolism noted that normalization of IGF-1 generally improves mood, but supraphysiologic GH states can produce restlessness and fluid retention 18.

Practical Threshold

Users who report anxiety or sleep-onset difficulty on MK-677 should consider whether their daily caffeine intake exceeds 200 mg and whether any caffeine is consumed after noon. Reducing caffeine to less than 200 mg before 12:00 PM is a low-risk first intervention before adjusting the MK-677 dose.

Dosing and Timing Guidance

The clinical picture across the above sections supports a straightforward timing protocol for users combining MK-677 and caffeine.

MK-677 Timing

Most published RCTs dosed MK-677 in the evening, capitalizing on nocturnal GH pulsatility 13. Morning dosing is pharmacokinetically equivalent in terms of IGF-1 area-under-the-curve at 24 hours, but evening dosing may produce a larger acute GH pulse amplitude. The choice should depend on tolerability (water retention and vivid dreams are more common with evening dosing).

Caffeine Timing

Based on the Drake et al. Data showing that caffeine consumed 6 hours before bed still reduces sleep quality 7, a last-caffeine cutoff of 6 hours before target sleep time is a defensible minimum. For users who are slow CYP1A2 metabolizers, extending this to 8 to 10 hours is appropriate.

Dose of Caffeine

Total daily caffeine below 200 mg is associated with minimal cortisol elevation and minor sleep architecture disruption compared to 400 mg or more 10. The FDA considers 400 mg/day safe for healthy adults, but this threshold does not account for the specific GH-sleep interaction relevant to MK-677 users 17.

Special Populations

Pre-Diabetic or Insulin-Resistant Users

Both MK-677 and caffeine impair insulin sensitivity through separate mechanisms. Pre-diabetic users (fasting glucose 100 to 125 mg/dL, HbA1c 5.7 to 6.4%) should monitor fasting glucose weekly during MK-677 initiation and keep caffeine to less than 200 mg/day. The ADA recommends HbA1c monitoring every 3 months in individuals at high risk for progression 14.

Older Adults

The Murphy et al. Trial enrolled adults aged 60 to 81 years 1. Caffeine half-life lengthens with age due to reduced CYP1A2 activity. Adults over 65 may need an earlier caffeine cutoff, closer to 8 to 10 hours before sleep, to avoid the same degree of slow-wave sleep suppression as a younger adult with a 6-hour cutoff.

Individuals on CYP3A4 Inhibitors

Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) will increase MK-677 plasma exposure. Caffeine does not inhibit CYP3A4 and does not compound this specific risk. However, users on CYP3A4 inhibitors for other indications should disclose MK-677 use to their prescribing clinician, as MK-677 plasma levels may rise substantially.